NovaBridge Plans Phase 2b Program For VIS-101 In Wet-AMD In H2,2026;FY25 Net Loss Widens; Stock Up

NovaBridge Biosciences announced full-year financial results for the year ended Dec. 31, 2025 and provided business updates on its lead investigational programs Givastomig and VIS-101. The release was factual and program-focused with no material financial metrics or forward guidance disclosed; near-term market impact is likely limited until clinical or financial specifics are provided.

Analysis

NovaBridge Biosciences announced full-year financial results for the year ended Dec. 31, 2025 and provided business updates on its lead investigational programs Givastomig and VIS-101. The release was factual and program-focused with no material financial metrics or forward guidance disclosed; near-term market impact is likely limited until clinical or financial specifics are provided.